VCA
GILD icon

Verdence Capital Advisors’s Gilead Sciences GILD Stock Holding History

Verdence Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$871K Sell
6,250
-4,905
-44% -$687K 0.05% 314
2025
Q4 		$1.37M Sell
11,155
-1,806
-14% -$219K 0.08% 232
2025
Q3 		$1.56M Sell
12,961
-2,060
-14% -$234K 0.09% 217
2025
Q2 		$1.67M Sell
15,021
-5,191
-26% -$552K 0.11% 184
2025
Q1 		$2.26M Sell
20,212
-4,514
-18% -$466K 0.17% 128
2024
Q4 		$2.28M Sell
24,726
-1,973
-7% -$178K 0.18% 133
2024
Q3 		$2.24M Buy
26,699
+3,261
+14% +$249K 0.18% 148
2024
Q2 		$1.61M Buy
23,438
+2,929
+14% +$195K 0.14% 177
2024
Q1 		$1.5M Buy
20,509
+7,249
+55% +$557K 0.14% 185
2023
Q4 		$1.07M Sell
13,260
-166
-1% -$12.9K 0.1% 208
2023
Q3 		$1.01M Buy
13,426
+2,069
+18% +$159K 0.11% 208
2023
Q2 		$875K Sell
11,357
-4,227
-27% -$337K 0.1% 216
2023
Q1 		$1.29M Sell
15,584
-9,346
-37% -$774K 0.16% 158
2022
Q4 		$2.14M Sell
24,930
-3,732
-13% -$296K 0.26% 93
2022
Q3 		$1.77M Buy
28,662
+1,505
+6% +$94.9K 0.24% 109
2022
Q2 		$1.68M Buy
27,157
+525
+2% +$32.5K 0.22% 118
2022
Q1 		$1.58M Buy
26,632
+5,354
+25% +$342K 0.18% 130
2021
Q4 		$1.54M Buy
21,278
+700
+3% +$48.2K 0.18% 126
2021
Q3 		$1.44M Buy
20,578
+493
+2% +$34.6K 0.19% 128
2021
Q2 		$1.38M Buy
20,085
+2,406
+14% +$161K 0.19% 122
2021
Q1 		$1.14M Buy
17,679
+11,152
+171% +$719K 0.19% 131
2020
Q4 		$380K Sell
6,527
-5,805
-47% -$350K 0.07% 248
2020
Q3 		$779K Buy
12,332
+6,758
+121% +$469K 0.18% 136
2020
Q2 		$429K Sell
5,574
-9,180
-62% -$704K 0.11% 201
2020
Q1 		$1.1M Buy
14,754
+1,473
+11% +$102K 0.33% 84
2019
Q4 		$863K Sell
13,281
-695
-5% -$45.3K 0.21% 116
2019
Q3 		$886K Buy
+13,976
New +$914K 0.25% 118
2018
Q2 		– Sell
-4,674
Closed -$352K – 300
2018
Q1 		$352K Sell
4,674
-3,451
-42% -$274K 0.08% 200
2017
Q4 		$582K Buy
+8,125
New +$617K 0.14% 135

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Verdence Capital Advisors's GILD Position: Q1 2026 in Review

Verdence Capital Advisors reduced its Gilead Sciences (GILD) stake by 44% in Q1 2026, selling an estimated $687K and leaving 6,250 shares worth $871K. The position accounts for 0.05% of the portfolio, ranked #314.

Verdence Capital Advisors first reported a position in GILD in Q4 2017 and has held it in 29 quarters since. The position peaked at $2.28M in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Verdence Capital Advisors held 6,250 shares of Gilead Sciences worth $871K as of Q1 2026.
  • Verdence Capital Advisors sold 4,905 Gilead Sciences shares in Q1 2026, an estimated $687K.
  • Gilead Sciences made up 0.05% of Verdence Capital Advisors's portfolio in Q1 2026, its #314 holding.
  • Verdence Capital Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 29 quarters since.
  • Verdence Capital Advisors's Gilead Sciences position peaked at $2.28M in Q4 2024.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.